Spaglumic acid is primarily used in the field of neuroscience and pharmacology due to its role as a selective antagonist for the NMDA (N-methyl-D-aspartate) receptor. It is particularly effective in modulating glutamate activity, which is crucial in various neurological conditions. Research has explored its potential in treating neurodegenerative diseases, such as Alzheimer's and Parkinson's, by protecting neurons from excitotoxicity caused by excessive glutamate signaling. Additionally, it has been studied for its neuroprotective effects in stroke and traumatic brain injury, where it helps reduce neuronal damage. Spaglumic acid is also being investigated for its potential in managing psychiatric disorders, including schizophrenia and depression, by regulating glutamate pathways. Its ability to modulate NMDA receptors makes it a promising candidate for therapeutic applications in neurological and psychiatric research.